医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Steven Barker Awarded the 2015 IAMPOV Lifetime Achievement Award

2015年10月14日 PM09:03
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

Masimo (NASDAQ: MASI) announced today that a member of its Board of Directors, Chairman of its Scientific Advisory Board, and its Chief Science Officer, Dr. Steven Barker, Ph.D., M.D., was honored with the Harvey W. Weiley Lifetime Achievement Award at this month’s Innovations and Applications of Monitoring Perfusion, Oxygenation, and Ventilation (IAMPOV) Symposium, in Tokyo, Japan.

“We are pleased to recognize Dr. Steven Barker as the winner of the 2015 IAMPOV Lifetime Achievement Award,” said Dr. Katsuyuki Miyasaka, IAMPOV Symposium Chair. “Dr. Barker was selected based on his lifelong work in championing the development of vitally important monitoring technologies and associated testing.”

The IAMPOV Symposium brings together clinicians, device developers, and researchers for an interchange of expertise and ideas to promote the development of better healthcare monitoring technologies and to improve their application in the areas of perfusion, oxygenation, and ventilation.

“We congratulate Dr. Steven Barker for this Lifetime Achievement award,” said Joe Kiani, Founder and CEO of Masimo. “Steve has been on the cutting edge of research in the areas of oxygen transport, oxygen saturation monitoring, dyshemoglobins, brain function monitoring, and many other patient monitoring modalities. His steadfast commitment to science and advancements in the area of patient care is second to none. Steve’s work has helped shed light on the problems and advancements in the area of oxygen transport.”

Steven J. Barker, PhD, MD, received his PhD in Aeronautical Engineering from the California Institute of Technology in 1972, and his MD from the University of Miami in 1981. He has reached the rank of tenured professor in both engineering (University of California at Los Angeles) and anesthesiology (University of California at Irvine, University of Arizona). He chaired the Department of Anesthesiology at UC Irvine from 1990 to 1995, and then at the University of Arizona from 1995 to 2013. He has published over 150 scholarly works, including 15 textbook chapters. Dr. Barker has served as president of the national organization of anesthesiology department chairs (AAPD) and of the Society for Technology in Anesthesia (STA), senior oral examiner for the American Board of Anesthesiology, and Section Editor for Technology for the journal Anesthesia and Analgesia. During his 18-year tenure as anesthesiology chair at the University of Arizona, Dr. Barker was active in a number of governance roles outside of his department. He also served seven years as the American Society of Anesthesiologists (ASA) Director for Academic Anesthesiology, representing all university anesthesiology departments for ASA. Since 2005, Dr. Barker has been a member of Masimo’s Board of Directors and Chairman of Masimo’s Scientific Advisory Board. In 2015, Dr. Barker also took on the role of Chief Science Officer of Masimo.

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014005631/en/

CONTACT

Masimo
Irene Paiga, 858-859-7001
irenep@masimo.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表